Page 79 - Read Online

Miliotis et al. J Cancer Metastasis Treat 2020;6:13 I http://dx.doi.org/10.20517/2394-4722.2020.12 Page 13 of 15

patients with early stage non-small cell lung cancer. Gene 2017;599:28-35.
43. Wu Y, Zhao T, Jia Z, Cao D, Cao X, et al. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression
and prognosis in gastric cancer. J Gastroenterol Hepatol 2019;34:1201-7.
44. Wang W, Sun J, Li F, Li R, Gu Y, et al. A frequent somatic mutation in CD274 3’-UTR leads to protein over-expression in gastric cancer
by disrupting miR-570 binding. Hum Mutat 2012;33:480-4.
45. Wang Q, Lin W, Tang X, Li S, Guo L, et al. The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. Int
J Mol Sci 2017;18:2540.
46. Wang F, Li T, Zhang B, Li H, Wu Q, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting
PTEN. Biochem Biophys Res Commun 2013;434:688-94.
47. Wang Y, Wang D, Xie G, Yin Y, Zhao E, et al. MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma.
Oncotarget 2017;8:28125-34.
48. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour
cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
49. Treece AL, Duncan DL, Tang W, Elmore S, Morgan DR, et al. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma
reveal cancer-associated and Epstein-Barr virus-related expression patterns. Lab Invest 2016;96:661-71.
50. Alessandrini L, Manchi M, De Re V, Dolcetti R, Canzonieri V. Proposed molecular and miRNA classification of gastric cancer. Int J Mol
Sci 2018;19:1683.
51. Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy.
Oncotarget 2015;6:6472-98.
52. Marquitz AR, Mathur A, Chugh PE, Dittmer DP, Raab-Traub N. Expression profile of microRNAs in Epstein-Barr virus-infected AGS
gastric carcinoma cells. J Virol 2014;88:1389-93.
53. Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, et al. Downregulation of microRNA-200 in EBV-associated gastric carcinoma.
Cancer Res 2010;70:4719-27.
54. Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, et al. Genome-wide identification of Epstein-Barr virus-driven promoter methylation
profiles of human genes in gastric cancer cells. Cancer 2013;119:304-12.
55. Queen KJ, Shi M, Zhang F, Cvek U, Scott RS. Epstein-Barr virus-induced epigenetic alterations following transient infection. Int J
Cancer 2013;132:2076-86.
56. Li Y, Nie Y, Tu S, Wang H, Zhou Y, et al. Epigenetically deregulated miR-200c is involved in a negative feedback loop with DNMT3a in
gastric cancer cells. Oncol Rep 2016;36:2108-16.
57. Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint
PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 2019;33:132-47.
58. Zhou Y, Ding BZ, Lin YP, Wang HB. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly
targeting HK1. Gene 2018;644:56-65.
59. Kim SM, Hur DY, Hong SW, Kim JH. EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in
gastric cancer cells. Biochem Biophys Res Commun 2017;494:550-5.
60. Otsuka H, Fukao A, Funakami Y, Duncan KE, Fujiwara T. Emerging evidence of translational control by AU-rich element-binding
proteins. Front Genet 2019;10:332.
61. Guo J, Qu H, Shan T, Chen Y, Chen Y, et al. Tristetraprolin overexpression in gastric cancer cells suppresses PD-L1 expression and
inhibits tumor progression by enhancing antitumor immunity. Mol Cells 2018;41:653-64.
62. Deng K, Wang H, Shan T, Chen Y, Zhou H, et al. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33. Sci Rep
2016;6:24505.
63. Sung WW, Chu YC, Chen PR, Liao MH, Lee JW. Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in
nasopharyngeal carcinoma cells. Cancer Lett 2016;382:21-31.
64. Wang M, Yu F, Wu W, Wang Y, Ding H, et al. Epstein-Barr virus-encoded microRNAs as regulators in host immune responses. Int J Biol
Sci 2018;14:565-76.
65. Hooykaas MJ, Kruse E, Wiertz EJ, Lebbink RJ. Comprehensive profiling of functional Epstein-Barr virus miRNA expression in human
cell lines. BMC Genomics 2016;17:644.
66. Qiu J, Smith P, Leahy L, Thorley-Lawson DA. The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo. PLoS
Pathog 2015;11:e1004561.
67. Yang YC, Liem A, Lambert PF, Sugden B. Dissecting the regulation of EBV’s BART miRNAs in carcinomas. Virology 2017;505:148-54.
68. Zhang J, Huang T, Zhou Y, Cheng ASL, Yu J, et al. The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-
associated gastric carcinoma. J Cell Mol Med 2018;22:38-45.
69. Tsai CY, Liu YY, Liu KH, Hsu JT, Chen TC, et al. Comprehensive profiling of virus microRNAs of Epstein-Barr virus-associated gastric
carcinoma: highlighting the interactions of ebv-Bart9 and host tumor cells. J Gastroenterol Hepatol 2017;32:82-91.
70. Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, et al. EBV microRNA-BHRF1-2-5p targets the 3’UTR of immune checkpoint
ligands PD-L1 and PD-L2. Blood 2019;134:2261-70.
71. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines.
PLoS Pathog 2012;8:e1002484.
72. Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, et al. DIANA-TarBase v7.0: indexing more than half a
million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res 2015;43:D153-9.